When you come to a stock pick website like this and see a random story that ;predicts a company will have great revenue growth going forward, hey, I get that you might not pull the trigger right away and bury yourself in stock. After all, there’s a lot of stock pickers out there and, frankly, the vast majority are absolute bullshit.
Equity.Guru, on the other hand, doesn’t often make predictions on companies we cover because the moment we lose you some money, you’re never coming back. We like to play it cool, and make sure what we talk about can be backed up by hard data.
That said, all the numbers on Medexus Pharma this past few months have had one thing in common: They didn’t make sense.
The revenues were up, and consistently so. The product line was being added to, and with low cost to the company. And though one of their products, Treosulfan, has taken far longer than hoped to clear US FDA approval, without that the company is in great shape.. with FDA approval? Well, that’ll be nuts.
Meanwhile, the company was selling for just $1.14 a share one month ago, good for a market cap of just CAD $24m, despite annual revenue of over US$100m.
So we yelled about it and, I guess you listened, you peppy little enthusiasts.
$2.06! A near double in one month!
In the perverse arena of the health industry, Medexus Pharmaceuticals Inc., that renegade of the medical establishment, dropped a revenue bombshell, just as predicted. Their revenue predictions for fiscal Q1 2024 are forecast to shatter records like a runaway freight train, and friends, I can’t say we didn’t see this coming because we stood outside our usual comfort zone and called it.
We said they’d climb, and damn, they’re climbing like a meth-fuelled mountain goat. Medexus is claiming a piece of the future, and it’s all happening in U.S. greenbacks.
These figures, to be clear, are still on the operating table – they’re fresh, they’re hot, they’re writhing, and they’re projections, which means the guys with pointy pencils still need to sign off on them and the eventual totals may swing in one direction or another.
The prophets at Medexus are whispering numbers in the realm of $31-million to $31.5-million for the quarter. That’s not just an impressive haul for fiscal Q1 2024, it’s a jaw-dropping, heart-stopping, record-breaking sum, if they can hit it. Compared to Q1 2023, we’re looking at a surge of at least 34.5 per cent – a financial blitzkrieg.
Ken d’Entremont, the head honcho at Medexus, can hardly contain his glee. “We’re damn thrilled with these numbers,” he confessed in a news release, a twinkle in his eye.
The standout performer, the MVP, the thoroughbred in the stable? It’s a drug called Rupall. “Even at the low end, we’re smashing records and making waves,” says KD’e.
Marcel Konrad, the chief moneyman at Medexus, chimed in, “This revenue explosion keeps us in the fast lane, cruising towards our forecast of a whopping $20-million in cold, hard cash come Sept. 30, 2023.”
So who is this Medexus, you ask? It’s a juggernaut in the specialty pharma world, a North American powerhouse with an ever-expanding portfolio of shiny new treatment solutions. The folks at Medexus are putting their chips on therapeutic goldmines like oncology, hematology, rheumatology, auto-immune diseases, allergies, and dermatology, and rather than research new medications, they specialize in bringing existing medications to the US and Canada. They’re big, but they haven’t been without issues. A recent concern about debt coming due was deftly handled by management, and the Treosulfan approval they’re hoping for will be a big fat cherry on top.
So let’s raise a glass to Medexus, the magic eight ball of the pharmaceutical world. You heard it here first. The trail they’re blazing is on fire, and for mine I honestly believe we’re at the start of this train’s journey. Buckle up and hold on, this thing is building steam.
— Chris Parry
FULL DISCLOSURE: Medexus has been an Equity.Guru marketing client in the past, we continue to hold stock in the company, and we’re talking about it today because we LOVE IT when a plan comes together.
